219 related articles for article (PubMed ID: 30937584)
1. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
[TBL] [Abstract][Full Text] [Related]
2. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
3. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
6. Hepatocellular Adenoma Subtypes Based on 2017 Classification System: Exploratory Study of Gadoxetate Disodium-Enhanced MRI Features With Proposal of a Diagnostic Algorithm.
Tse JR; Felker ER; Cao JJ; Naini BV; Liang T; Lu DSK; Raman SS
AJR Am J Roentgenol; 2023 Apr; 220(4):539-550. PubMed ID: 36169546
[No Abstract] [Full Text] [Related]
7. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
[TBL] [Abstract][Full Text] [Related]
8. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
9. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.
Denecke T; Steffen IG; Agarwal S; Seehofer D; Kröncke T; Hänninen EL; Kramme IB; Neuhaus P; Saini S; Hamm B; Grieser C
Eur Radiol; 2012 Aug; 22(8):1769-75. PubMed ID: 22437921
[TBL] [Abstract][Full Text] [Related]
10. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
12. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
14. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
15. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
16. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.
McInnes MD; Hibbert RM; Inácio JR; Schieda N
Radiology; 2015 Nov; 277(2):413-23. PubMed ID: 26020440
[TBL] [Abstract][Full Text] [Related]
17. Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI.
Ünal E; İdilman İS; Karaosmanoğlu AD; Özmen MN; Akata D; Karcaaltıncaba M
Diagn Interv Radiol; 2019 Nov; 25(6):416-420. PubMed ID: 31650968
[TBL] [Abstract][Full Text] [Related]
18. Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.
Tse JR; Naini BV; Lu DS; Raman SS
Radiology; 2016 Apr; 279(1):118-27. PubMed ID: 26505921
[TBL] [Abstract][Full Text] [Related]
19. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
Chen CY; Chen J; Xia CC; Huang ZX; Song B
J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
[TBL] [Abstract][Full Text] [Related]
20. Subtyping of hepatocellular adenomas using Gd-EOB-DTPA: a qualitative and quantitative analysis.
Schaible J; Schreyer AG; Mehrabi A; Longerich T; Kieser M; Kreimeyer S; Klauss M; Grenacher L
Acta Radiol; 2023 Jul; 64(7):2253-2260. PubMed ID: 36650712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
